Market Overview

Edwards Lifesciences Confirms Appeals Court Ruling of Medtronic's Willful Infringement of Transcatheter Valve Patent

Share:
Related EW
Edwards Lifesciences Paints A Picture Of A Compelling Future
The Technical Take On Edwards Lifesciences
Related MDT
DexCom Jumps 25% As It Becomes Only Continuous Glucose Monitoring With Medicare Coverage
The MedTech Group: 2017 Top Picks And Catalysts
D.R. Horton, Shell, FCX, senior loans among picks at Barron's Roundtable (Seeking Alpha)

Edwards Lifesciences Corporation (NYSE: EW) announced that the U.S. Court of Appeals for the Federal Circuit today affirmed an April 2010 federal jury decision that Medtronic (NYSE: MDT) CoreValve LLC is willfully infringing Edwards' U.S. Andersen transcatheter heart valve patent. The Appeals Court also ordered the trial court to reconsider Edwards' request for a permanent injunction that would prohibit the manufacture and sale of the CoreValve System in the United States. In addition, the Court affirmed the validity of this patent and the federal jury's verdict awarding an initial payment of $74 million in damages to Edwards, which covers infringement through early 2010.

Posted-In: News Legal

 

Related Articles (EW + MDT)

View Comments and Join the Discussion!